Stock Analysis on Net
Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

Common-Size Income Statement

Boston Scientific Corp., common-size consolidated income statement

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net sales 100.00 100.00 100.00 100.00 100.00
Cost of products sold -31.19 -31.22 -34.95 -29.02 -28.63
Gross profit 68.81% 68.78% 65.05% 70.98% 71.37%
Selling, general and administrative expenses -35.63 -36.66 -38.21 -36.71 -36.34
Research and development expenses -10.43 -10.13 -11.53 -10.94 -11.33
Royalty expense -0.37 -0.41 -0.45 -0.61 -0.71
Amortization expense -6.33 -6.23 -7.96 -6.51 -6.10
Goodwill impairment charges 0.00 0.00 -0.74 0.00 0.00
Intangible asset impairment charges -1.04 -3.11 -4.64 -0.98 -0.36
Contingent consideration net (expense) benefit -0.28 1.14 1.01 0.33 0.21
Restructuring net charges -0.19 -0.34 -0.52 -0.35 -0.37
Litigation-related net charges -1.36 -3.62 -2.80 -1.07 -1.05
Gain (loss) on disposal of businesses and assets -0.17 0.66 0.00 0.00 0.00
Operating expenses -55.81% -58.70% -65.85% -56.84% -56.04%
Operating income (loss) 13.00% 10.09% -0.81% 14.14% 15.33%
Interest expense -3.71 -2.87 -3.64 -4.41 -2.45
Other, net -0.30 1.83 3.65 -3.33 1.60
Other income (expense) -4.01% -1.03% 0.01% -7.74% -0.86%
Income (loss) before income taxes 9.00% 9.05% -0.80% 6.40% 14.48%
Income tax (expense) benefit -3.49 -0.29 -0.03 37.38 2.53
Net income (loss) 5.50% 8.76% -0.83% 43.78% 17.01%
Preferred stock dividends -0.44 -0.47 -0.33 0.00 0.00
Net income (loss) available to common stockholders 5.06% 8.29% -1.16% 43.78% 17.01%

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Income statement item Description The company
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Boston Scientific Corp. operating income (loss) as a percentage of net sales increased from 2020 to 2021 and from 2021 to 2022.
Income (loss) before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Boston Scientific Corp. income (loss) before income taxes as a percentage of net sales increased from 2020 to 2021 but then slightly decreased from 2021 to 2022.
Net income (loss) The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Boston Scientific Corp. net income (loss) as a percentage of net sales increased from 2020 to 2021 but then slightly decreased from 2021 to 2022.